Cisplatin at clinically relevant concentrations enhances interleukin-2 synthesis by human primary blood lymphocytes.

Important note: Information in this article was accurate in 1999. The state of the art may have changed since the publication date.

Cisplatin at clinically relevant concentrations enhances interleukin-2 synthesis by human primary blood lymphocytes.

Anticancer Drugs. 1999 Feb;10(2):219-27. Unique Identifier : AIDSLINE MED/99226535
Riesbeck K; Department of Medical Microbiology, Malmo University Hospital,; Lund University, Sweden. kristian.riesbeck@mikrobiol.mas.lu.se

Abstract: Cytotoxic drugs influence the expression of certain genes in cancer cells. Cisplatin has recently been shown to modulate interleukin (IL)-1 and tumor necrosis factor (TNF)-alpha production in macrophages. In this study, we wanted to investigate whether cisplatin interferes with the IL-2, IL-2 receptor (IL-2R), interferon (IFN)-gamma, and TNF-alpha expression in phytohemagglutinin-stimulated human peripheral blood lymphocytes. IL-2 was analyzed in a bioassay, while IFN-gamma and TNF-alpha were measured by ELISA. Northern blots were performed to quantify steady-state cytokine mRNA levels. Furthermore, T cell subsets and IL-2R surface expression were analyzed by means of flow cytometry. A maximum stimulatory effect on IL-2 production (1.8-fold increase) was observed with cisplatin at 5-10 microM while IFN-gamma and TNF-alpha synthesis and IL-2R density were unaffected. However, cisplatin-treated cells displayed enhanced IL-2, IL-2R, IFN-gamma and TNF-alpha mRNA levels compared to drug-free controls. Cisplatin did not prolong cytokine mRNA half-life as revealed with the transcriptional inhibitor actinomycin D. In contrast to an inhibited growth of CD4+ T lymphocytes, CD3+ CD8+ cell density was unaffected at intermediate cisplatin concentrations (10 microM). Bleomycin, carboplatin, doxorubicin, novobiocin or etoposide, which were included for comparison, did not interfere with IL-2 expression. Our data imply that cisplatin most likely stimulated cytokine transcription via a putative stress-induced signaling pathway.

Keywords: JOURNAL ARTICLE Antineoplastic Agents/*ADMINISTRATION & DOSAGE Cell Division/DRUG EFFECTS Cells, Cultured/DRUG EFFECTS Cisplatin/*ADMINISTRATION & DOSAGE CD4-Positive T-Lymphocytes/DRUG EFFECTS/METABOLISM CD8-Positive T-Lymphocytes/DRUG EFFECTS/METABOLISM Dose-Response Relationship, Drug DNA/BIOSYNTHESIS/DRUG EFFECTS Human Interferon Type II/DRUG EFFECTS/GENETICS/METABOLISM Interleukin-2/*BIOSYNTHESIS/GENETICS Lymphocytes/*DRUG EFFECTS/METABOLISM Phytohemagglutinins/PHARMACOLOGY Support, Non-U.S. Gov't Transcription, Genetic Tumor Necrosis Factor/DRUG EFFECTS/GENETICS/METABOLISM
990830
A9980937

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .